This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lien, Y.-C. Articles by St. Clair, D. K. Search for Related Content PubMed PubMed Citation Articles by Lien, Y.-C. Articles by St. Clair, D. K. Related Collections Commentary

¹ Graduate Center for Toxicology, University of Kentucky, Lexington, Kentucky; ² Department of Pathology and Laboratory Medicine Service, William S. Middleton Veterans Memorial Hospital, University of Wisconsin, Madison, Wisconsin; and ³ Faculty of Medical Technology, Mahidol University, Bangkok, Thailand

Requests for reprints: Daret K. St. Clair, Graduate Center for Toxicology, University of Kentucky, 454 Health Sciences Research Building, Lexington, KY 40536. Phone: 859-257-3956; Fax: 859-323-1059. E-mail: dstcl00{at}uky.edu

Cardiomyopathy is a major dose-limiting factor for applications of Adriamycin, a potent chemotherapeutic agent. The present study tested the hypothesis that increased tumor necrosis factor (TNF)- signaling via its receptors protects against Adriamycin-induced cardiac injury. We used mice in which both TNF receptor I and II have been selectively inactivated (DKO) with wild-type mice as controls. Morphometric studies of cardiac tissue following Adriamycin treatment revealed greater ultrastructural damage in cardiomyocyte mitochondria from DKO mice. Biochemical studies of cardiac tissues showed cytochrome c release and the increase in proapoptotic protein levels, suggesting that lack of TNF- receptor I and II exacerbates Adriamycin-induced cardiac injury. The protective role of TNF receptor I and II was directly confirmed in isolated primary cardiomyocytes. Interestingly, following Adriamycin treatment, the levels of Fas decreased in the wild-type mice. In contrast, DKO mice had an increase in Fas levels and its downstream target, mitochondrial truncated Bid. These results suggested that TNF- receptors play a critical role in cardioprotection by suppression of the mitochondrial-mediated associated cell death pathway. [Mol Cancer Ther 2006;5(2):261–9]

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: The current address for Y-C. Lien is Center for Radiological Research, College of Physicians and Surgeons, Columbia University, New York, NY 10032. The current address for S-M. Lin is Nutritional Science, Chung Hwa College of Medical Technology, 717 Tainan, Taiwan. The current address for Q. Zhao is Department of Biochemistry, Guangzhou Medical College, 510182 Guangzhou, China.

⁴ Unpublished data.

Received 9/27/05; revised 11/ 3/05; accepted 11/22/05.

Commentary

Is p21 an oncogene?

Andrei L. Gartel
Mol. Cancer Ther. 2006 5: 1385-1386. [Full Text] [PDF]

This article has been cited by other articles:

				R. Nithipongvanitch, W. Ittarat, J. M. Velez, R. Zhao, D. K. St. Clair, and T. D. Oberley Evidence for p53 as Guardian of the Cardiomyocyte Mitochondrial Genome Following Acute Adriamycin Treatment J. Histochem. Cytochem., June 1, 2007; 55(6): 629 - 639. [Abstract] [Full Text] [PDF]

				Y.-C. Lien, T. Noel, H. Liu, A. J. Stromberg, K.-C. Chen, and D. K. St. Clair Phospholipase C-{delta}1 Is a Critical Target for Tumor Necrosis Factor Receptor-Mediated Protection against Adriamycin-Induced Cardiac Injury. Cancer Res., April 15, 2006; 66(8): 4329 - 4338. [Abstract] [Full Text] [PDF]